Novel drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others.
麻豆原创 Analysis and Insights: Global Pharmaceutics and Novel Drug Delivery Systems 麻豆原创
The global Pharmaceutics and Novel Drug Delivery Systems market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Pharmaceutics and Novel Drug Delivery Systems market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Pharmaceutics and Novel Drug Delivery Systems, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Pharmaceutics and Novel Drug Delivery Systems, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pharmaceutics and Novel Drug Delivery Systems revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Pharmaceutics and Novel Drug Delivery Systems market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Pharmaceutics and Novel Drug Delivery Systems revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
Segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein鈥揹rug Conjugates
Other
Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Pharmaceutics and Novel Drug Delivery Systems in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutics and Novel Drug Delivery Systems companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmaceutics and Novel Drug Delivery Systems revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Liposomes
1.2.3 PEGylated Proteins & Polypeptides
1.2.4 Polymer Nanoparticle
1.2.5 Protein鈥揹rug Conjugates
1.2.6 Other
1.3 麻豆原创 by Application
1.3.1 Global Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals & Clinic
1.3.3 Cancer Treatment Centers
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Perspective (2019-2030)
2.2 Global Pharmaceutics and Novel Drug Delivery Systems Growth Trends by Region
2.2.1 Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pharmaceutics and Novel Drug Delivery Systems Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Pharmaceutics and Novel Drug Delivery Systems Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Dynamics
2.3.1 Pharmaceutics and Novel Drug Delivery Systems Industry Trends
2.3.2 Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Drivers
2.3.3 Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Challenges
2.3.4 Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Pharmaceutics and Novel Drug Delivery Systems by Players
3.1.1 Global Pharmaceutics and Novel Drug Delivery Systems Revenue by Players (2019-2024)
3.1.2 Global Pharmaceutics and Novel Drug Delivery Systems Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Pharmaceutics and Novel Drug Delivery Systems, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Concentration Ratio
3.4.1 Global Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutics and Novel Drug Delivery Systems Revenue in 2023
3.5 Global Key Players of Pharmaceutics and Novel Drug Delivery Systems Head office and Area Served
3.6 Global Key Players of Pharmaceutics and Novel Drug Delivery Systems, Product and Application
3.7 Global Key Players of Pharmaceutics and Novel Drug Delivery Systems, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutics and Novel Drug Delivery Systems Breakdown Data by Type
4.1 Global Pharmaceutics and Novel Drug Delivery Systems Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Pharmaceutics and Novel Drug Delivery Systems Forecasted 麻豆原创 Size by Type (2025-2030)
5 Pharmaceutics and Novel Drug Delivery Systems Breakdown Data by Application
5.1 Global Pharmaceutics and Novel Drug Delivery Systems Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Pharmaceutics and Novel Drug Delivery Systems Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size (2019-2030)
6.2 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type
6.2.1 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Type (2019-2030)
6.3 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application
6.3.1 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Application (2019-2030)
6.4 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country
6.4.1 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size (2019-2030)
7.2 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type
7.2.1 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Type (2019-2030)
7.3 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application
7.3.1 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Application (2019-2030)
7.4 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country
7.4.1 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size (2019-2030)
8.2 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type
8.2.1 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2019-2024)
8.2.2 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2025-2030)
8.2.3 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Type (2019-2030)
8.3 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application
8.3.1 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2019-2024)
8.3.2 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2025-2030)
8.3.3 China Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size (2019-2030)
9.2 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type
9.2.1 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Type (2019-2030)
9.3 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application
9.3.1 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Application (2019-2030)
9.4 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Region
9.4.1 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Pharmaceutics and Novel Drug Delivery Systems 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Pharmaceutics and Novel Drug Delivery Systems Introduction
11.1.4 Amgen Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.1.5 Amgen Recent Developments
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Pharmaceutics and Novel Drug Delivery Systems Introduction
11.2.4 Teva Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.2.5 Teva Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Pharmaceutics and Novel Drug Delivery Systems Introduction
11.3.4 Roche Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.3.5 Roche Recent Developments
11.4 UCB (Union Chimique Belge)
11.4.1 UCB (Union Chimique Belge) Company Details
11.4.2 UCB (Union Chimique Belge) Business Overview
11.4.3 UCB (Union Chimique Belge) Pharmaceutics and Novel Drug Delivery Systems Introduction
11.4.4 UCB (Union Chimique Belge) Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.4.5 UCB (Union Chimique Belge) Recent Developments
11.5 Celgene
11.5.1 Celgene Company Details
11.5.2 Celgene Business Overview
11.5.3 Celgene Pharmaceutics and Novel Drug Delivery Systems Introduction
11.5.4 Celgene Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.5.5 Celgene Recent Developments
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Pharmaceutics and Novel Drug Delivery Systems Introduction
11.6.4 Merck Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.6.5 Merck Recent Developments
11.7 Gilead Sciences
11.7.1 Gilead Sciences Company Details
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Pharmaceutics and Novel Drug Delivery Systems Introduction
11.7.4 Gilead Sciences Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.7.5 Gilead Sciences Recent Developments
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Pharmaceutics and Novel Drug Delivery Systems Introduction
11.8.4 Sanofi Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.8.5 Sanofi Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Pharmaceutics and Novel Drug Delivery Systems Introduction
11.9.4 Pfizer Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.9.5 Pfizer Recent Developments
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Pharmaceutics and Novel Drug Delivery Systems Introduction
11.10.4 Takeda Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.10.5 Takeda Recent Developments
11.11 Bausch&Lomb
11.11.1 Bausch&Lomb Company Details
11.11.2 Bausch&Lomb Business Overview
11.11.3 Bausch&Lomb Pharmaceutics and Novel Drug Delivery Systems Introduction
11.11.4 Bausch&Lomb Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.11.5 Bausch&Lomb Recent Developments
11.12 Samyang Biopharmaceuticals
11.12.1 Samyang Biopharmaceuticals Company Details
11.12.2 Samyang Biopharmaceuticals Business Overview
11.12.3 Samyang Biopharmaceuticals Pharmaceutics and Novel Drug Delivery Systems Introduction
11.12.4 Samyang Biopharmaceuticals Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.12.5 Samyang Biopharmaceuticals Recent Developments
11.13 Johnson & Johnson
11.13.1 Johnson & Johnson Company Details
11.13.2 Johnson & Johnson Business Overview
11.13.3 Johnson & Johnson Pharmaceutics and Novel Drug Delivery Systems Introduction
11.13.4 Johnson & Johnson Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.13.5 Johnson & Johnson Recent Developments
11.14 TOLMAR
11.14.1 TOLMAR Company Details
11.14.2 TOLMAR Business Overview
11.14.3 TOLMAR Pharmaceutics and Novel Drug Delivery Systems Introduction
11.14.4 TOLMAR Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.14.5 TOLMAR Recent Developments
11.15 Astellas
11.15.1 Astellas Company Details
11.15.2 Astellas Business Overview
11.15.3 Astellas Pharmaceutics and Novel Drug Delivery Systems Introduction
11.15.4 Astellas Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.15.5 Astellas Recent Developments
11.16 AMAG Pharmaceuticals
11.16.1 AMAG Pharmaceuticals Company Details
11.16.2 AMAG Pharmaceuticals Business Overview
11.16.3 AMAG Pharmaceuticals Pharmaceutics and Novel Drug Delivery Systems Introduction
11.16.4 AMAG Pharmaceuticals Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.16.5 AMAG Pharmaceuticals Recent Developments
11.17 AbbVie
11.17.1 AbbVie Company Details
11.17.2 AbbVie Business Overview
11.17.3 AbbVie Pharmaceutics and Novel Drug Delivery Systems Introduction
11.17.4 AbbVie Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.17.5 AbbVie Recent Developments
11.18 Dr Reddy
11.18.1 Dr Reddy Company Details
11.18.2 Dr Reddy Business Overview
11.18.3 Dr Reddy Pharmaceutics and Novel Drug Delivery Systems Introduction
11.18.4 Dr Reddy Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.18.5 Dr Reddy Recent Developments
11.19 AstraZeneca
11.19.1 AstraZeneca Company Details
11.19.2 AstraZeneca Business Overview
11.19.3 AstraZeneca Pharmaceutics and Novel Drug Delivery Systems Introduction
11.19.4 AstraZeneca Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.19.5 AstraZeneca Recent Developments
11.20 Aspen
11.20.1 Aspen Company Details
11.20.2 Aspen Business Overview
11.20.3 Aspen Pharmaceutics and Novel Drug Delivery Systems Introduction
11.20.4 Aspen Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.20.5 Aspen Recent Developments
11.21 Acrotech Biopharma
11.21.1 Acrotech Biopharma Company Details
11.21.2 Acrotech Biopharma Business Overview
11.21.3 Acrotech Biopharma Pharmaceutics and Novel Drug Delivery Systems Introduction
11.21.4 Acrotech Biopharma Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.21.5 Acrotech Biopharma Recent Developments
11.22 TWi Pharmaceuticals
11.22.1 TWi Pharmaceuticals Company Details
11.22.2 TWi Pharmaceuticals Business Overview
11.22.3 TWi Pharmaceuticals Pharmaceutics and Novel Drug Delivery Systems Introduction
11.22.4 TWi Pharmaceuticals Revenue in Pharmaceutics and Novel Drug Delivery Systems Business (2019-2024)
11.22.5 TWi Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
听
听
*If Applicable.
